Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

21. Oral diclofenac no longer available without prescription

Oral diclofenac no longer available without prescription Oral diclofenac no longer available without prescription - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Oral diclofenac no longer available without prescription Oral diclofenac is associated with a small increased risk of cardiovascular side effects and is therefore no longer available over the counter. Published 22 January 2015 From: Therapeutic area: , When prescribing or dispensing diclofenac, consider that: oral (...) diclofenac must not be sold without prescription a for non-prescription diclofenac the in June 2013 topical formulations of diclofenac (eg gel and cream) remain available for sale over the counter Advice to give to patients: if you have recently bought diclofenac tablets without a prescription and continue to need pain relief, speak to your prescriber or pharmacist who can advise you on suitable alternatives - there is no problem if you wish to stop taking diclofenac in the meantime if you have been

2015 MHRA Drug Safety Update

22. Artotec (diclofenac sodium, misoprostol) - treatment of rheumatic diseases

Artotec (diclofenac sodium, misoprostol) - treatment of rheumatic diseases HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 ARTOTEC 50 mg/0.2 mg, tablet B/30 (CIP: 34009 336 492 6 5) ARTOTEC 75 mg/0.2 mg, tablet B/20 (CIP: 34009 352 654 7 0) Applicant: PFIZER INN diclofenac sodium, misoprostol ATC code (2012) M01AB55 (Antiinflammatory (...) and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based medicines at the Committee’s request, in compliance with Article R-163-21 of the French Social Security Code Lists concerned National Health Insurance (French Social Security Code L.162-17) Inclusion for hospital use (French Public Health Code L.5123-2) Indications concerned ARTOTEC 50 mg/0.2 mg: “Symptomatic treatment of rheumatic diseases in at-risk patients

2014 Haute Autorite de sante

23. Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc

Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 FLECTOR 50 mg, granules for oral solution in single-dose sachets (...) B/21 (CIP: 34009 352 642 9 9) Applicant: GENEVRIER INN diclofenac epolamine ATC code (2012) M01AB05 (Antiinflammatory and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based medicines at the Committee’s request, in compliance with Article R-163-21 of the French Social Security Code Lists concerned National Health Insurance (French Social Security Code L.162-17) Inclusion for hospital use (French Public

2014 Haute Autorite de sante

24. Voltarendolo (diclofenac potassium) - Symptomatic treatment of painful conditions of mild to moderate intensity and/or fever

Voltarendolo (diclofenac potassium) - Symptomatic treatment of painful conditions of mild to moderate intensity and/or fever HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 VOLTARENDOLO 12.5 mg, coated tablet B/30 tablets (CIP: 34009 359 411 2 1) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN diclofenac potassium ATC Code (2012 (...) ): N02BG (Other analgesics and antipyretics) Reason for the review Re-assessment of the Actual Benefit of all medicines based on diclofenac administered systemically at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code Renewal of inclusion on the list of medicinal products refundable by National Health Insurance Lists concerned National Health Insurance (French Social Security Code L.162 17) Hospital use (French Public Health Code L.5123-2) Indication

2014 Haute Autorite de sante

25. Voltarene (diclofenac sodium)

Voltarene (diclofenac sodium) HAS - Medical, Economic and Public Health Assessment Division 1/40 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 VOLTARENE 25 mg, gastro-resistant coated tablet B/30 (CIP: 34009 338 144 5 8) VOLTARENE 50 mg, gastro-resistant coated tablet B/30 (CIP: 34009 323 511 7 6) VOLTARENE LP 75 mg, prolonged-release coated tablet B/30 (CIP: 34009 335 920 4 2) VOLTARENE LP 100 mg (...) , prolonged-release coated tablet B/15 (CIP: 34009 324 604 9 6) VOLTARENE ENFANT, suppository B/10 (CIP: 34009 322 395 3 5) VOLTARENE 100 mg, suppository B/10 (CIP: 34009 322 143 4 1) VOLTARENE 75 mg/3 ml, solution for injection B/2 (CIP: 34009 324 522 2 4) Applicant: NOVARTIS PHARMA SAS INN diclofenac sodium ATC code (2012) M01AB05 (Antiinflammatory and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based

2014 Haute Autorite de sante

26. Systematic review: the effectiveness and safety of diclofenac for the pain management after cesarean

Systematic review: the effectiveness and safety of diclofenac for the pain management after cesarean Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2014 PROSPERO

27. Diclofenac

Diclofenac USE OF DICLOFENAC IN PREGNANCY 0344 892 0909 USE OF DICLOFENAC IN PREGNANCY (Date of issue: July 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used (...) to treat acute and chronic pain (including dysmenorrhoea) and in the management of rheumatoid arthritis. Some studies have suggested that use of NSAIDs in early pregnancy may be associated with an increased risk of spontaneous abortion. Data regarding diclofenac use are insufficient to assess the risk for this specific NSAID. NSAID use in pregnancy has been associated with increased risks of various different congenital malformations, including cardiovascular defects and oral clefts. No association

2014 UK Teratology Information Service

28. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial (Abstract)

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients (...) not confirm osteonecrosis in any patient.Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required.NCT00864097.Published by the BMJ Publishing Group Limited. For permission to use (where

2013 EvidenceUpdates Controlled trial quality: predicted high

29. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Full Text available with Trip Pro

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Brereton N, Winn B, Akehurst (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI), compared with diclofenac plus a PPI, for patients with osteoarthritis. The authors

2013 NHS Economic Evaluation Database.

30. Diclofenac: public consultation on availability as a pharmacy medicine

Diclofenac: public consultation on availability as a pharmacy medicine Diclofenac: public consultation on availability as a pharmacy medicine - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Diclofenac: public consultation on availability as a pharmacy medicine Public consultation launched on the continued availability of oral diclofenac as a pharmacy (P) medicine and on risk-minimisation measures advised by the Commission on Human Medicines. Published 11 December 2014 From (...) : Therapeutic area: Article date: August 2013 We have launched a public consultation on the continued availability of oral diclofenac as a pharmacy (P) medicine and in particular on risk-minimisation measures advised by the Commission on Human Medicines. Any comments can be emailed to ; alternatively they may be addressed to: Colette McCreedy, Self Medication Specialist and Unit Manager, MHRA, 3rd Floor, 151 Buckingham Palace Road, London SW1W 9SZ. Comments must arrive no later than 28 October 2013

2013 MHRA Drug Safety Update

31. Diclofenac: new contraindications and warnings Full Text available with Trip Pro

Diclofenac: new contraindications and warnings Diclofenac: new contraindications and warnings - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Diclofenac: new contraindications and warnings New recommendations after a Europe-wide review of cardiovascular safety. Published 11 December 2014 From: Therapeutic area: , , Contents Article date: June 2013 An increased risk of heart attack and stroke with some non-selective non-steroidal anti-inflammatory drugs (NSAIDs (...) )—such as diclofenac—is well recognised, particularly with long-term use of high doses and in patients who are already at high risk. Warnings for healthcare professionals and patients have been included in the product information and in the British National Formulary for some years. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has recently recommended updates to the treatment advice for diclofenac in light of the findings of a Europe-wide review of the cardiovascular safety of NSAIDs

2013 MHRA Drug Safety Update

32. Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder

Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder UTCAT2225, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder Clinical Question In a patient suffering from Temporomandibular Joint Disorder (...) , is topical administration of treatment as effective when compared to systemic administration of treatment in alleviating ailments? Clinical Bottom Line Topical administration of diclofenac is as effective as systemic administration in alleviating ailments of temporomandibular joint disorder. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Di Rienzo/2004 36 adult patients diagnosed with dysfunction of the TMJ

2012 UTHSCSA Dental School CAT Library

33. Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management of Large Joint Osteoarthritis: A Systematic Review

Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management of Large Joint Osteoarthritis: A Systematic Review "Efficacy of Oral Enzyme Combination vs. Diclofenac in the Management o" by Scott T. Hall < > > > > > Title Author Date of Graduation Summer 8-9-2012 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers PA-C, MS Rights . Abstract Background: Osteoarthritis is the most common (...) and trypsin. The purpose of this review is to evaluate the efficacy of oral enzyme combinations to the potent NSAID diclofenac in the management of osteoarthritis. Method: An extensive literature search was done using CINHAL, Medline, Evidence-Based Medicine Reviews Multifile, and Web of Science. The search included the terms Bromelain, Arthritis and Non-Steroidal Anti-inflammatory agents. Results: Five randomized control trials met the inclusion criteria. Each study was very similar with respect to study

2012 Pacific University EBM Capstone Project

34. Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions

Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

35. Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries

Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Kuehl KS CRD summary The review concluded that diclofenac epolamine (...) topical patch 1.3% significantly reduced pain in patients with soft tissue injuries and was well tolerated. Given the potential for bias in the review and the limitations of the small evidence base (such as uncertain quality and heterogeneity), the author's conclusions should be interpreted with caution. Authors' objectives To assess the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in the treatment of patients with acute pain due to soft tissue injuries. Searching MEDLINE

2010 DARE.

36. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. (Abstract)

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective NSAIDs plus a proton-pump inhibitor (PPI) have similar upper gastrointestinal outcomes, but risk of clinical outcomes across the entire gastrointestinal tract might be lower with selective drugs than with non-selective drugs. We aimed to compare risk of gastrointestinal (...) events associated with celecoxib versus diclofenac slow release plus omeprazole.We undertook a 6-month, double-blind, randomised trial in patients with osteoarthritis or rheumatoid arthritis at increased gastrointestinal risk at 196 centres in 32 countries or territories. Patients tested negative for Helicobacter pylori and were aged 60 years and older or 18 years and older with previous gastroduodenal ulceration. We used a computer-generated randomisation schedule to assign patients in a 1:1 ratio

2010 Lancet Controlled trial quality: predicted high

37. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness

Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Tsakonas E, Argaez C Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tsakonas E, Argaez C. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions The studies reviewed for this report suggest that in general, topical diclofenac (in gel and patch formulations), is safe and effective

2009 Health Technology Assessment (HTA) Database.

38. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac (Abstract)

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac Nonsteroidal anti-inflammatory drugs (NSAIDs) cause lower gastrointestinal (GI) clinical events such as bleeding. Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events.Patients >or=50 years old with osteoarthritis (...) or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd). Lower GI clinical events, confirmed by a blinded adjudication committee, included perforation or obstruction requiring hospitalization or bleeding (gross or occult rectal bleeding without upper GI cause associated with hypotension, orthostatic changes in heart rate [>20 beats per minute] or blood pressure [>20 mmHg systolic or >10 mmHg diastolic], hemoglobin drop >or=2 g/dl, or transfusion; or observed

2008 EvidenceUpdates Controlled trial quality: predicted high

39. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) (Abstract)

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032 (...) ) or diclofenac 75 mg twice daily (n = 2054). Use of gastroprotective agents and low-dose aspirin was allowed. The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs). General safety was also assessed, including adjudicated thrombotic cardiovascular event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).Mean (SD; maximum) duration of treatment was 19.3

2008 EvidenceUpdates Controlled trial quality: predicted high

40. Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain

Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Article Text Therapeutics Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain

2008 Evidence-Based Medicine